Drugs that contain Cabotegravir; Rilpivirine

1. List of Cabenuva Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(a month from now)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(4 years from now)

US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

NCE-1 date: January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatment of hiv infection in adults; Treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

67

United States

35

European Union

23

Japan

21

Hungary

21

Norway

16

Spain

14

Korea, Republic of

13

Slovenia

13

Denmark

12

Australia

12

Lithuania

11

Poland

11

Portugal

11

China

10

Brazil

9

Hong Kong

9

Israel

9

Mexico

8

Cyprus

8

EA

8

Croatia

8

Canada

8

Taiwan, Province of China

7

Luxembourg

6

Ukraine

6

South Africa

6

New Zealand

5

AP

4

Austria

4

Argentina

3

RS

3

Netherlands

3

Belgium

2

Morocco

2

Chile

2

Malaysia

2

Jordan

2

Singapore

2

ME

2

Costa Rica

2

Nicaragua

1

Viet Nam

1

Uruguay

1

Germany

1

OA

1

Egypt

1

Peru

1

Philippines

1

Panama

1

San Marino

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic